EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characterization of rimegepant drug–drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam

Rajinder Bhardwaj, Beth Morris, Kyle T Matschke, Richard Bertz, Robert Croop, Jing Liu

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Rajinder Bhardwaj und 5 weiteren Autor:innen. Beteiligte Einrichtung: Certara USA, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Fluconazole, Itraconazole, Midazolam. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was sponsored by Biohaven, which was acquired by Pfizer in October 2022.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Reported here are the results of four rimegepant phase I studies, in healthy participants, aimed at determining the in vivo potential of rimegepant (75 mg) for cytochrome P450 (CYP) 3A4‐related drug–drug interactions (DDIs).

Background

Rimegepant orally disintegrating tablet (Pfizer Inc., New York, NY, USA) is a calcitonin gene‐related peptide receptor antagonist approved for acute treatment of migraine and preventive treatment of episodic migraine. People with migraine commonly use multiple drug treatments, with the potential for DDIs.

Methods

Each study was an open‐label, single‐arm, single‐sequence, crossover study. Rimegepant was tested as a victim drug by separate co‐administration of itraconazole (a strong CYP3A4 inhibitor and P‐glycoprotein inhibitor) in Study 1, rifampin (a strong CYP3A4 inducer and moderate CYP2C9 inducer) in Study 2, and fluconazole (a strong CYP2C9 inhibitor and moderate CYP3A4 inhibitor) in Study 3, and as a perpetrator drug by co‐administration with midazolam (a CYP3A4 substrate) in Study 4.

Results

Mean values of single‐dose rimegepant maximum concentration (C max ) and area under the curve from time 0 to infinity (AUC 0–inf ) increased with itraconazole co‐administration ( n = 22) by 1.42‐fold (90% confidence interval [CI] 1.25–1.61) and by 4.14‐fold (90% CI 3.87–4.44), respectively, and decreased with rifampin co‐administration ( n = 21) to 36% (90% CI 31.2–41.4%) and to 19% (90% CI 16.3–21.4%), respectively. Co‐administration with fluconazole ( n = 23) increased rimegepant mean AUC 0–inf by 1.80‐fold (90% CI 1.68–1.93), with no impact on C max (1.04‐fold; 90% CI 0.94–1.15). Co‐administration of rimegepant single dose (300 mg; n = 14) or multiple doses (150 mg/day; n = 14) increased the mean C max of midazolam by 1.38‐fold (90% CI 1.13–1.67) and 1.53‐fold (90% CI 1.32–1.78), respectively, and the AUC 0–inf of midazolam by 1.86‐fold (90% CI 1.58–2.19) and 1.91‐fold (90% CI 1.63–2.25), respectively.

Conclusions

Based on the magnitude of DDIs, these studies indicate the following: co‐administration of rimegepant with a strong CYP3A4 inhibitor should be avoided; during co‐administration with a moderate CYP3A4 inhibitor, another dose of rimegepant within 48 h should be avoided; co‐administration of rimegepant with a strong or moderate CYP3A4 inducer should be avoided; CYP2C9 does not play a meaningful role in rimegepant metabolism; and there is no clinically meaningful CYP3A4 inhibition by rimegepant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related Peptide Receptor AntagonistsFluconazoleItraconazoleMidazolamPiperidinesPyridinesRifampinAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultCross-Over StudiesCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsDrug InteractionsClinical Trials, Phase I as Topic

Stichwörter der Autor:innen

calcitonin gene‐related peptidedrug–drug interactionsmigrainepharmacokineticsphase‐I clinical studyrimegepant

Substanzen

Calcitonin Gene-Related Peptide Receptor AntagonistsCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsFluconazoleItraconazoleMidazolamPiperidinesPyridinesRifampinrimegepant sulfate

Autor:innen und Institutionen

  • Certara USA, Princeton, New Jersey, USA.
  • Biohaven Pharmaceuticals, Inc, New Haven, Connecticut, USA.
  • Pfizer Inc, Groton, Connecticut, USA.

Förderung

  • This study was sponsored by Biohaven, which was acquired by Pfizer in October 2022

Zitieren

APA

Bhardwaj, R., Morris, B., Matschke, K. T., Bertz, R., Croop, R., & Liu, J. (2025). Characterization of rimegepant drug–drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14836

Vancouver

Bhardwaj R, Morris B, Matschke KT, Bertz R, Croop R, Liu J. Characterization of rimegepant drug–drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14836

BibTeX
@article{Bhardwaj2025,
  author = {Bhardwaj, Rajinder and Morris, Beth and Matschke, Kyle T and Bertz, Richard and Croop, Robert and Liu, Jing},
  title = {Characterization of rimegepant drug–drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14836}
}
Kostenlos starten →